Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU
Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status 3. Histology
Early stage Potentially resectable disease Locally advanced : unresectable disease Metastatic disease
Early stage Surgery then Adjuvant CT in stage IIa,IIb Potentially resectable disease IA IB Locally advanced : unresectable disease IIA IIB Metastatic disease IIA
Early stage (resectable disease) Adjuvant Chemotherapy begin at stage IIA (IB +/- ; Category 2B)
Adjuvant Trials Scorecard Trials Stage IA Stage IB Stage II Stage IIIA 2004 Japan Negative Positive Not tested Not tested 2003ALPI Negative Negative Negative Negative 2004 IALT Negative Negative Negative Positive 2004CALGB Not tested Negative Not tested Not tested 2005JBR10 Not tested Negative Positive Not tested 2005ANITA Not tested Negative Positive Positive
Adjuvant Chemo in NSCLC; with what? Patient Regimen 1st Agent 2nd Agent Fit,young - best NP q 3 x 4 Vinorelbine 25-30 D1,8 Cis 75-80 D1 Fit,young - alternative EP q 3-4 x 4 Etoposide 100 D1-3 Cis 100 D1 Acceptable regimen GC q 3 x 4 Gem 1250 D1,8 Cis 75 D1 Pt with comorbid, not tolerate cis TCar q 3 x 4 Taxol 200 D1 Carbo AUC 6 D1
Stage I,II,III (except IA)
Early stage Potentially resectable disease Locally advanced : unresectable disease Metastatic disease
Confirm pathologic N2 (if possible)
Early stage Potentially resectable disease Locally advanced : unresectable disease Metastatic disease
Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status 3. Histology
American Society of Clinical Oncology Clinical Practice Guideline on CT for stage IV NSCLC Azzoli C, Baker S, Temin S, et al. JCO 2009
First line treatment in NSCLC ASCO Detail R A1 CT indicate in ECOG 0,1 possibly 2 R A2 PS 0,1 = 2 drugs Platinum preferred R A3 Single CT in PS 2 R A4 R A5 R A6 R A7 R A8 Not use age alone in decide Either Cis or Carbo are acceptable 1 line should be stop at PD, or after 4 in NR 1 line Gefitinib may be for pt EGFR mutation Bev + tax/carboplatin recommend except SCC R A9 Cet + V/C may consider in EGFR +
V 2012
Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status 3. Histology
Histological type of NSCLC / / / /
Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status 3. Histology Squamous cell carcinoma Non-squamous cell carcinoma - Adenocarcinoma - Large cell carcinoma
Squamous histology Clinical Male,smoker Clinical Central,cavitation Small cell Squamous cell CA Molecul ar Ras and EGFR mutation rare High TS and EGFR over expression common
Smoker adeno histology Non smoker - adeno histology Clinical Clinical Molecul ar Male,smoker Peripheral,pleural disease High ras mutation, EGFR over expression, low EGFR mutation, low TS Clinical Clinical Molecular Female, non smoker, asian Peripheral, multifocal,ground glass appearance Frequent EGFR mutation, EGFR over expression Ras mutation rare, low TS
From pathology to molecular biology 1. EGFR mutation + : EGFR-TKIs 2. EGFR over expression : EGFR-Mob (cetuximab) 3. EML4-ALK translocation : Crizotinib
Systemic Treatment Options in NSCLC 1. Standard doublet chemotherapy 2. Targeted therapy with EGFR-TKIs - Gefitinib, Erlotinib 3. Targeted therapy plus standard chemotherapy - Bevacizumab plus GC or TCar - Cetuximab plus VC
Limitation of 1 st line doublet CT in NSCLC Survival: ECOG 1594 1 st line 3 rd generation chemotherapy in NSCLC RR = 19 % TTP = 3.6 months MST = 7.9 months 1 yr survival = 33% 2 yr survival = 11% Schiller et al. NEJM 2002.
Does histology matter... For the selection of CT in NSCLC
Squamous histology Clinical Male,smoker Clinical Central,cavitation Small cell Squamous cell CA Molecul ar Ras and EGFR mutation rare High TS and EGFR over expression common
Smoker adeno histology Non smoker - adeno histology Clinical Clinical Molecul ar Male,smoker Peripheral,pleural disease High ras mutation, EGFR over expression, low EGFR mutation, low TS Clinical Clinical Molecular Female, non smoker, asian Peripheral, multifocal,ground glass appearance Frequent EGFR mutation, EGFR over expression Ras mutation rare, low TS Pemetrexed
CONSORT: Phase III Gemcitabine or Pemetrexed + Cisplatin as First-line Therapy Advanced-stage, previously untreated NSCLC patients (N = 1725) Stratified by: ECOG PS (0 vs 1) Disease stage (IIIB vs IV) Brain metastases (yes vs no) Sex (male vs female) Pathologic diagnosis (histologic vs cytologic) Treatment center Cisplatin 75 mg/m 2 on Day 1 Gemcitabine 1250 mg/m 2 on Days 1 and 8 Six 3-wk cycles Cisplatin 75 mg/m 2 on Day 1 Pemetrexed 500 mg/m 2 on Day 1 Six 3-wk cycles Scagliotti GV, et al. J Clin Oncol. 2008;26:3543-3551.
CONSORT: Efficacy Survival Median OS, mos Pemetrexed + Cisplatin (n = 862) 10.3 10.3 Gemcitabine + Cisplatin (n = 863) HR (95% CI) 0.94 (0.84-1.05) P Value Noninfe rior Adenocarcinoma (N = 847) Large-cell carcinoma (N = 153) Squamous cell carcinoma (N = 473) 12.6 10.9 10.4 6.7 9.4 10.8 0.84 (0.71-0.99).03 0.67 (0.48-0.96).03 1.23 (1.00-1.51).05 Scagliotti GV, et al. J Clin Oncol. 2008;26:3543-3551.
Targeted Therapy in NSCLC 1. Target at tumor cells - over expression of EGFR : cetuximab - EGFR mutation : TKIs 2. Target at vascular endothelial cells - Inc VEGF : anti-vegf (bevacizumab )
EGFR expression in NSCLC x x x x
Proposed MoA of Bevacizumab : A dynamic effect throughout treatment EARLY EFFECTS CONTINUED EFFECTS 1 Regression 2 Normalization 3 Inhibition Decreases tumour size Improves delivery of CTx Suppresses new vessel growth Suppresses regrowth via vessel scaffolds
Bevacizumab plus TCarb in non-squamous NSCLC E4599: OS 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 OS estimate Overall population CP 10.3 12.3 Bevacizumab 15mg/kg + CP 0 6 12 182430 36 42 Months Median OS (months) CP: 10.3 Bevacizumab 15mg/kg + CP: 12.3 HR=0.79; p=0.003 OS estimate Adenocarcinoma* 1.0 0.9 CP 0.8 Bevacizumab 15mg/kg + CP 0.7 0.6 0.5 0.4 0.3 0.2 0.1 10.3 14.2 0 0 6 12 182430 36 42 48 Months Median OS (months) CP: 10.3 Bevacizumab 15mg/kg + CP: 14.2 HR=0.69 1. Sandler, et al. NEJM 20062. Sandler, et al. JTO 2010 (in press)
Only PFS benefit in AVAiL (Bevacizumab+GC in non-squamous NSCLC) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 PFS estimate E4599 1 Bev 15mg/kg + CP CP 0 6 1218 2430 Time (months) 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 AVAiL 2 Bev 7.5mg/kg + CG Bev 15mg/kg + CG Placebo + CG 0 6 12 1824 30 Time (months) Bevacizumab 15mg/kg Bevacizumab 7.5mg/kg Bevacizumab 15mg/kg Median PFS 6.2 vs 4.5 months HR=0.66; p<0.001 6.7 vs 6.1 months HR=0.75; p=0.003 6.5 vs 6.1 months HR=0.82; p=0.03 Pre-planned analysis applying the same censoring rules to both trials 3 HR=0.68; p<0.0001 HR=0.74; p=0.0021 1. Sandler, et al. NEJM 2006; 2. Reck, et al. JCO 2009 3. Sandler, et al. ECCO 2007
EGFR expression in NSCLC EGFR TKIs x x x x
Role of EGFR-TKIs in NSCLC Clinical selection - Female - Non smoker - Asian ethnicity - Adenocarcinoma histo
Role of EGFR-TKIs in NSCLC Clinical selection Molecular selection - Female - Non smoker - EGFR mutation - EGFR amplification - Asian ethnicity - Adenocarcinoma histo
NSCLC patients with somatic mutation of EGFR have been shown to be hyperresponsive to the EGFR TKIs The most common NSCLC-associated EGFR mutations are In-frame deletion in exon 19 (E746-A750del) Point mutation in exon 21 (L858R) 46% 39%
Mutations in EGFR TK in Unselected Patients With NSCLC Subgroup Tumors Screened, n Mutations Mean % (Range) United States 262 25 9 (2-14) Europe 860 39 5 (NR) Australia 83 6 7 (NR) Eastern Asia 1273 413 32 (26-40) Adenocarcinoma 907 245 27 (9-55) Other histology 837 9 1 (0-3) Men 865 108 12 (6-32) Women 369 143 38 (20-59) Smokers 662 66 10 (5-22) Nonsmokers 517 180 35 (12-69) Haber DA, et al. AACR 2005.
IPASS biomarkers study
At least 2 positive clinical factors (1 = Asean ethnicity)
V 2012
Overall survival (ITT population) Gefitinib CBDCA/TXL (n=98) Logrank (n=100) test Median survival 28.0 23.6 m HR (95%CI) 0.793 (0.485-1.296) p value* 0.354 Overall survival (%) *Log-rank test 2-year survival rate Gefitinib 61% CBDCA/TXL 45% Inoue et al. ECCO-ESMO 2009; Abstract 9LBA
Summary Overall population HRQoL endpoints were consistent with efficacy outcomes in IPASS EGFR M+ population Improvement rates in HRQoL and symptoms significantly favored gefitinib over C/P Times to worsening of HRQoL and symptoms were substantially longer for gefitinib than C/P Median time to improvement in HRQoL and symptoms were as rapid as 8 days with gefitinib in patients who improved EGFR M- population Improvement rates in HRQoL and symptoms significantly favored C/P over gefitinib Times to worsening for HRQoL and symptoms were longer for C/P than gefitinib Thongprasert et al. ELCC 2010; Abstract 205O
EURTAC : First-line Erlotinib vs Chemo in European Patients With EGFR Mutations 174 patients Trial run in Europe (lead by Spanish group) Outcome CT Erlotinib HR P Value Response rate, % 15 58 - NR Median PFS, mos 5.2 9.7 0.37 <.0001 Median OS, mos NR NR 0.80.42 Most common toxicities, % ALT elevation: 72 Anemia: 46 Neutropenia: 36 ALT elevation: 80 Rash: 80 Diarrhea: 57 Rosell R, et al. ASCO 2011. Abstract 7503.
Evidence based management decision for 1st line NSCLC good ECOG EGFR mutation + EGFR unknown Squamous CA Non-squamous EGFR TKIs Traditional 3rd gen doublet CT (non-pemetrexed) Bev + doublet CT Or Pem doublet CT Or Traditional CT
ASCO : Recommendations ECOG 0-1 :1 st -line platinum doublet (4 6 cycles) ECOG 2 : single agent CT Wait and Watch policy 2nd-line treatment Diagnosis CR,PR or SD PD PD When should 1 st line be stopped 1. PD while on treatment 2. After 4 cycles in patient whose disease is not responding to Px (SD) 3. 2 drug combinations should be administered for no more than 6 cycles American Society of Clinical Oncology CPG update on chemotherapy for stage IV NSCLC. JCO 2009.
Second line treatment in Advanced NSCLC BSC Docetaxel Pemetrexed Erlotinib 2000 2004 2005
2004: pemetrexed versus docetaxel efficacy and tolerability 1.00 D (n=276) P (n=265) Median OS (mos) 7.9 8.3 Variable Pemetrexed Docetaxel p-value Overall response (%) 9.1 8.8 NS Progression-free survival, median (mos) 2.9 2.9 NS Time to progression, median (mos) 3.4 3.5 NS 0.75 1-yr survival (%) 29.7 29.7 Duration of response, median (mos) 4.6 5.3 NS OS probability 0.50 0.25 0 Pemetrexed Docetaxel HR=0.99 (0.8 1.2) Survival time, median (mos) 8.3 7.9 NS 1-year survival rate (%) 29.7 29.7 NS Neutropenia grade 3 4 (%) 5.3 40.2 <0.001 Febrile neutropenia (%) 1.9 12.7 <0.001 >1 hospitalisation for febrile neutropenia (%) 1.5 13.4 <0.001 G-CSF (%) 2.6 19.2 <0.001 >1 hospitalisation for any drugrelated AE (%) 6.4 10.5 0.092 0 510 1520 Time (months) Pemetrexed had similar efficacy to docetaxel with reduced haematological toxicity Hanna, et al. JCO 2004
2005: erlotinib showed OS advantage in pre-treated NSCLC (BR.21) 1.00 Erlotinib (n=488) Placebo (n=243) 0.75 Median OS (months) 6.7 4.7 OS probability 0.50 0.25 HR=0.73 (0.60 0.87), p=0.001* 0 0 5 10 1520 2530 Time (months) Shepherd, et al. NEJM 2005
Second line treatment in Advanced NSCLC Gefitinib? BSC Docetaxel Pemetrexed Erlotinib 2000 2004 2005
Maintenance Therapy Emerging Approach in NSCLC Historical approach First-line treatment Platinum doublet chemotherapy (4 6 cycles) Watch and wait Second and further lines of treatment Diagnosis CR/PR/SD PD PD Increased time to PD New approach Maintenance therapy Diagnosis CR/PR/SD PD PD
Summary of available clinical evidences of Maintenance therapy 1. Maintenance therapy with same drug : Continuation 1.1 Gem after GC x 4 1.2 Gem or Erlotinib after GC x 4 2. Maintenance therapy with different drug : Switching 2.2 Doc after GC x 4 2.1 Pem after GC x 4 (JMEN) 2.2 Erlotinib after GC x 4 (SATURN) 3. Maintenance therapy with Both 3.1 Bev + Erlotinib after Bev + CT (ATLAS)
JMEN (maintenance pemetrexed): PFS and OS in ITT population Patients with stage IIIB/IV NSCLC and PS 0 1 who had received 4 previous cycles of gemcitabine, docetaxel, or paclitaxel + platinum with CR, PR, or SD (n=663) R A N D O M I S E 2:1 Pemetrexed 500mg/m 2 on d1 q21d + BSC (n=441) Placebo on d1 q21d + BSC (n=222) PFS probability 1.0 0.8 0.6 0.4 0.2 Pemetrexed Placebo HR=0.60 (95% CI 0.49 0.73); p<0.0001 OS probability 1.0 0.8 0.6 0.4 0.2 Pemetrexed Placebo HR=0.79 (95% CI 0.65 0.95); p=0.012 0 06 1218 ITT=intent-to-treat Time (months) 0 06 12 18 24 30 36 42 Time (months) Ciuleanu, et al. Lancet 2009
Maintenance Pemetrexed : DFS Benefit of non-squamous histology Ciuleanu et al. Lancet 2009.
Evidence base systemic treatment in NSCLC stage IV
1st Line
1st Line 2nd Line Doublet Chemotherapy TCarb PemCis (Adenocarcinoma) GC 3rd Line Pemetrexed Docetaxel 4th Line AYC AYC
1st Line 2nd Line Docetaxel Docetaxel
1st Line 2nd Line Docetaxel 3rd Line EGFR-TKIs Docetaxel EGFR-TKIs